HealthBIO Vuosiseminaari Tero Piispanen, Turku Science Park Oy

Transkriptio

1 HealthBIO Vuosiseminaari Tero Piispanen, Turku Science Park Oy

2 -

3 Osaamiskeskusohjelma HealthBIO HealthBIO on bioteknologian terveyssovellusten ja terveyteen liittyvien liiketoiminta-alueiden klusteriohjelma, jonka keskeinen tavoite on liiketoiminnan synnyttäminen, kasvattaminen ja kansainvälistyminen Klusterin toiminta keskittyy suomalaisen bioalan huippuosaamisen hyödyntämiseen liiketoiminnassa tätä tukevien rakenteiden, toimintamallien ja muun osaamisen kehittämiseen Vuosina HB osaamiskeskuksiin on syntynyt jo 100 alan yritystä Ihmisen perimä Ihmisen hoito Ihmisen mittaus Ihmisen varaosat

4 Klusterin toiminnan painopisteet IHMISEN IHMISEN IHMISEN IHMISEN PERIMÄ MITTAAMINEN HOITO VARAOSAT Pk-seutu & Kuopio Oulu & Turku Kuopio & Turku Tampere Rahoituksen ja investointien aktivointi Arvoketjun kehittäminen ja uudet aloitteet Liiketoiminnan kasvu Kansainväliset asiakkaat ja kumppanit Rajapinnat: Hyvinvointi, ympäristö, elintarvikkeet, nano

5 Klusterin hankkeita 1/3 Rahoituksen ja investointien aktivointi Arvoketjun kehittäminen ja uudet aloitteet Liiketoiminnan kasvu Kansainväliset asiakkaat ja kumppanit Kansainvälisten T&K&I investointien houkuttelu - Receptor -hanke - Invest in Southern Finland

6 Klusterin hankkeita 2/3 Rahoituksen ja investointien aktivointi Arvoketjun kehittäminen ja uudet aloitteet Liiketoiminnan kasvu Kansainväliset asiakkaat ja kumppanit Tutkimusosaamisen ja liiketoiminnan yhteistyö - Tohtorien työelämävalmiudet -hanke - HealthPORT hanke (klinikasta liiketoiminnaksi) - Pilot case kilpailu asti

7 Klusterin hankkeita 3/3 Rahoituksen ja investointien aktivointi Arvoketjun kehittäminen ja uudet aloitteet Liiketoiminnan kasvu Kansainväliset asiakkaat ja kumppanit Uusien markkinoiden ja asiakkuuksien avaus - FiDiMoLAB-hanke (Venäjä) - Verkkovoimaa-hanke - MediGateway China-Finland -hanke

8 HealthBIO klusterin toiminnan painopisteitä

9 Fokuksena Venäjä

10 Muita kv-aktiviteetteja Brussels, October 7-9, 2012 Stockholm, 2013 in collaboration with Swedenbio Zürich, February 12, 2013 Spring 2013 in collaboration with Tekes Spring 2013 MediGateWay China project

11 Suomen bioala

12 17 New Start-ups Created Since Autumn 2011 Pääkaupunkiseutu: Desentum Oy Vaccine development Ingenious Diagnostics POC diagnostics for consumers Finbiosoft Oy Bioinformatics ErgoMedi Oy Healthcare instruments Halsing design R&D services Turku: Montisera Oy Drug discovery & services Labrox Oy Plate reader manufaturing Myhealthway Mhealth serv (diabetes) ID Creations Biomaterials Gutguide Bioanalytics Skulle implants Biomaterials Kuopio: Kasve Oy R&D services Tampere: Bioptima Oy Process optimization Heromed Oy Instrument design Oulu: Paras Biopharma Drug development Ecozymes Industrial enzymes Hiwellness Cell culture services

13 Success stories 09/11-09/12 Scientific & Product Milestones Orion received European marketing authorisation for dexdor (NCE) Biotie Selincro(TM) reduces total alcohol consumption by two-thirds on average after six months of treatment Laurantis Pharma Received positive Ph I results in Dry Eye Syndrome Oncos Therapeutics Patient recruitment started in C1 study Faron Pharmaceuticals Received positive Ph I/II results in acute lung injury Nexstim announces German landmark study on clinical value of Navigated Brain Stimulation for pre-surgical planning, published in the Journal of Neurosurgery

14 Success stories 09/11-09/12 Scientific & Product Milestones FIT Biotech co-develops new treatments for HIV infections with Boehringer Ingelheim, GSK Biologicals, Sanofi-Pasteur, ViiV Healthcare, Swiss Vaccine Research Institute and Vaccine Institute in France Faron Pharmaceuticals has initiated development of GMP manufacturing of the humanized anti-clever-1 antibody FP-1304 with Biovian (oncology) Pharmatest has found 15 new potential cancer drug candidates in a Eurostars project with Spanish and Romanian partners

15 Success stories 09/11-09/12 Selected Commercial Milestones Mendor Modz enters into a distribution deal with Merck Serono in the UK and with Mediq in the Baltic region. Has been awarded the TiE50 technology prize for innovations announces partnership with Novo Nordisk in the marketing of juvenile glucose meter. Has been chosen into the Red Herring 100 Europe Award list Planmeca announced a 70+ million order from Saudi Arabia Plexpress and Admescope announced collaboration in ADME-Tox tests and in vitro drug interactions investigations Biohit ArcDia signs distribution contract with EuroDiagnostica for GastroPanel signs a distribution agreement with Laboratorios Leti S.L.U for maripoc in Spain, Portugal, Andorra and Gibraltar

16 Success stories 09/11-09/12 Selected Financial News Orion turnover H1/2011 up 2% to 480M and gross profit to 145M (158M) HyTest turnover H1/2011 grew 18% to 6,3 M, gross profit 46% Bayer Mirena sales 581 M in 2011 Desentum completes 5M financing of which ca 1,5 M VC money Hermo Pharma Oy completes Series A round from Avera, Helsinki University Funds and private investors Plexpress announced up to $ 2,3 M funding with Conor Technology Fund, VTT Ventures, Avera and Helsinki University Funds

17 Success stories 09/10-09/11 Selected Financial News Biotie raises 30 M from Lundbeck, Invesco, UCB Pharma, others Lifeline Ventures announces 20 Million Fund. ArcDia raises 2,7 M to develop MariPOC business; Lifeline Ventures, Veraventure, private investors Abacus Diagnostica completes Series A financing with private investors Biosilta raises 1M from Fortel managmeent and Inveni Capital Neurotar completes 2nd round private investment.

18 Success stories 09/10-08/11 Acquisitions & Mergers Stick Tech has been acquired by Japanese GC corporation Biohit has sold its Liquid Handling business to Sartorius Foodfiles Oy and KPL Good Food Practises AB merge to create Foodfiles AB ID Creations Oy has acquired MetAlive Technology from Vivoxid Vivoxid has sold Fiberlive business to Purac Biochem b.v. (NL)

19 Rahoitus?

20 Money raised by Biotech Co s (Sept 3, 2012) world-wide $ Billion Source: BioCentury *Extrapolated to year end

21 Source: Ernst & Young European biotech financings $ million

22 Source: Burrill & Co (SME Loan) 100k k $

23 billion Buyout funding dominant in Europe (all sectors) Source: EVCA/PEREP_Analytics

24 European Venture Capital Investments 2011 ( 3,9 bn) Ca 1,7 M / Co (3143) %

25 Investments Made by Finnish VC s 2011 k.a / yritys Source: FVCA

26 Finnish Venture Capital 2011 M Source: FVCA

27 Venture Capital Investments into Finnish Co s 2011 Source: FVCA

28 Funds Managed by Finnish VC s Source: FVCA

29 European Clinical Pipeline UK D DK CH F SE I IS AUT ESP BEL NL IRL N FIN

30 US vs. Europe 1870 vs Co s US market cap is 4 x EU US generates revenue 3 x EU US sector employs 2 x EU Source: Ernst & Young

31 Trends?

32 Source: Burrill & Co

33 Source: Burrill & Co

34

35 Source: Burrill & Co

36 Personalized Medicine 90% of drugs work on % of individuals Targeted Therapy - Rational Rx based on molecular pathology Individualized Therapy - Rational Rx based on molecular profiling of individuals - Companion Dx Personalized Care - Transition to disease prediction - Real-time remote health monitoring SOURCE: George Poste, Burrill & Co

37 Source: Burrill & Co

38 Source: Burrill & Co

39

40 Kiitos!